Cytek Biosciences prelim Q4 revenue beats estimates

Cytek Biosciences

12/01/2026 10:10

Overview

Cell analysis firm's preliminary Q4 revenue rose 8% yr/yr, beating analyst expectations

Company's growth driven by services, reagents, and instrument sales in Asia Pacific, US, EMEA

Outlook

Cytek expects its total revenue for the full year 2025 to be approximately $201 million

Company sees sustainable growth and profitability in flow cytometry market

Result Drivers

SERVICES AND REAGENTS - Strong growth in services and reagents contributed significantly to Q4 revenue increase

ASIA PACIFIC INSTRUMENT SALES - Notable growth in instrument sales in Asia Pacific region supported revenue growth

EMEA INSTRUMENT SALES - Return to positive growth in EMEA instrument sales contributed to overall revenue growth

Key Details

Metric
Beat/Miss
Actual
Consensus Estimate
Q4 Revenue
Beat
$62 mln
$57.30 mln (4 Analysts)

Analyst Coverage

The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 2 "strong buy" or "buy", 3 "hold" and no "sell" or "strong sell"

The average consensus recommendation for the advanced medical equipment & technology peer group is "buy"

Wall Street's median 12-month price target for Cytek Biosciences Inc is $5.75, about 5.5% above its January 9 closing price of $5.45

Press Release: ID:nGNX3Yh35w

For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com.

(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)